Access Clinical Trials Decriminalization Safety 
NORML
JANUARY 4, 2019
Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?
Cannabis Law Report
JULY 1, 2021
Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. cities and the State of Oregon have decriminalized them, and last November, Oregon voters legalized the supervised administration of psilocybin. Background. Due to their therapeutic and commercial potential, the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
JULY 6, 2021
The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. Professor of Law at Harvard Law School. “By
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Published Via JD Supra. The state of the law on psychedelic substances is in flux. 360bbb-0a.
Cannabis Law Report
MAY 29, 2022
7] And cities around the country are beginning to decriminalize some psychedelics, with advocates for decriminalization citing the potential medical benefits. In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., Clinical Trials and Human Subject Protections.
The Cannigma
AUGUST 26, 2021
Medical: Legal Recreational: Illegal (though at least one territory has adopted decriminalization). The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. But only if it is made affordable and accessible.
Expert insights. Personalized for you.
125 
Let's personalize your content